| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | Receptor tyrosine kinase MerTK, C-Mer Proto-Oncogene Tyrosine Kinase, Mer, Proto-Oncogene C-Mer |
| Clonality | |
| Conjugate | |
| Host | |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Overview
Anti-MERTK (extracellular)-FITC Antibody is an antibody targeting Receptor tyrosine kinase MerTK, C-Mer Proto-Oncogene Tyrosine Kinase, Mer, Proto-Oncogene C-Mer Polyclonal raised in Rabbit (Fluorescein isothiocyanate (FITC)). This antibody is commonly used in FC, LCI to detect, localize, or compare expression of the target across samples.
Key elements and design rationale
- Target: Receptor tyrosine kinase MerTK, C-Mer Proto-Oncogene Tyrosine Kinase, Mer, Proto-Oncogene C-Mer (also reported as Receptor tyrosine kinase MerTK, C-Mer Proto-Oncogene Tyrosine Kinase, Mer, Proto-Oncogene C-Mer).
- Immunogen/epitope region: Extracellular, N-terminus..
- Homology note: Rat - identical; human - 13/15 amino acid residues identical (informative for cross-species interpretation).
- Species reactivity (as provided): Human, Rat, Mouse.
- Lot quality control (as provided): Western blot analysis (unlabeled antibody, #ATR-033), and direct flow cytometry (labeled antibody)..
- Peptide confirmation: Confirmed by amino acid analysis and mass spectrometry.
- Blocking peptide: Available for antigen preadsorption control where appropriate.
- Conjugate/format: Fluorescein isothiocyanate (FITC) (may affect detection channel and background).
These attributes help researchers interpret whether signal reflects the intended target in a given assay and sample context.
Biological background
Myeloid-epithelial-reproductive tyrosine kinase, MERTK, is a receptor tyrosine kinase of the TAM (Tyro3, Axl and MERTK) family, expressed in numerous cancers1.The extracellular N-terminal domain contains two immunoglobulin-like and two fibronectin 3 domains, followed by a hydrophobic single pass transmembrane domain, and a cytoplasmic C-terminal tail containing a tyrosine kinase domain1,2.Auto-phosphorylation induced by ligand binding influences a range of downstream signaling pathways and cellular functions2. The physiological roles of MERTK include regulation of tissue homeostasis and repair, innate immune control, and platelet aggregation. However, aberrant expression of this protein promotes neoplasia, cell cycle progression, proliferation and tumor growth, resistance to apoptosis, and promotion of tumor metastases.MERTK is involved in the activation of several canonic oncogenic signaling pathways in various types of cancers including: leukemia, non-small cell lung cancer, glioblastoma, melanoma, prostate cancer, breast cancer, colon cancer and gastric cancer1,3,4.Due to its pivotal role in cancer development and metastasis, multiple therapeutic approaches are currently in development to inhibit MERTK, including ligand "traps" and small-molecule tyrosine kinase inhibitors4.
Research relevance and current trends
- Comparing target expression across perturbations, genotypes, or treatment conditions.
- Interpreting localization shifts alongside pathway or phenotypic readouts.
- Using orthogonal controls (KO/KD, peptide competition, isotype concepts) to support conclusions.
Common research applications
- Flow cytometry (direct/indirect): quantify target-positive populations and shifts in expression across subsets.
- Live cell imaging (LCI): support extracellular-epitope detection on non-permeabilized cells when appropriate.
Interpretation typically benefits from comparing matched sample sets (e.g., treated vs control, WT vs KO/KD) and using orthogonal readouts where feasible.
Notes for experimental interpretation
- Isoforms and post-translational modifications can shift apparent molecular weight or epitope accessibility across samples.
- Cross-species signal may depend on epitope conservation; consult the provided homology note when selecting models.
- Permeabilization, fixation, and antigen retrieval can change accessibility of intracellular vs extracellular epitopes.
- Conceptual control: antigen preadsorption (blocking peptide) can help assess signal dependence on the immunogen region.
- Provided control suggestions: Negative control: RIC-001-F.
- Application notes: see product-specific dilution/usage notes and control concepts provided in the dataset.
Application abbreviations: CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA, IF- Immunofluorescence, IFC- Indirect flow cytometry, IHC- Immunohistochemistry, IP- Immunoprecipitation, LCI- Live cell imaging, N- Neutralization, WB- Western blot. Species abbreviations: H- Human, M- Mouse, R- Rat.
Recommended controls: Blocking peptide: BLP-TR033; Negative control: RIC-001-F.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
